MedTrace Logo

Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

NCT01974323 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2238

Last updated 2018-10-09

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Dapsone Gel

Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.

DRUG

Dapsone Gel Vehicle

Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01974323 on ClinicalTrials.gov